Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Apatech on fast track to success


1 October 2007

ApaTech, a global leader in synthetic bone graft technologies, has been recognized as Britain’s fastest growing private medical technology company.

‘The Sunday Times Microsoft Tech Track 100’ awards were announced on 30 September 2007 and ApaTech was ranked as 13th in the top 100, when measured by its outstanding sales performance over the two years to March 2007, which saw revenues grow at a compound annual growth rate of 238%

This award follows ApaTech’s recent appearance in the Financial Times on 22 August 2007, when it was ranked 9th in a UBS study of the UK’s fastest growing venture-backed companies. ApaTech is backed by 3i, MTI Partners and Bioscience Investment Trust, a fund managed by Schroders plc.

The tremendous sales growth of recent years reflects the rapid adoption of ApaTech’s leading product Actifuse™. Utilising unique silicon substituted calcium phosphate chemistry and novel manufacturing technologies to provide a scaffold that mimics natural bone, Actifuse stimulates and supports bone growth. Compared to earlier generation synthetic products Actifuse generates more, better quality bone in less time and being synthetic, avoids the issues associated with autograft or donated bone. This significant advance is increasingly being adopted worldwide by orthopaedic and neuro-surgeons in spine fusion, joint reconstruction and trauma applications.

The Company’s state-of-the-art production facility in Elstree, which was only opened last September by Lord Sainsbury, is already approaching full capacity and construction of a second facility is being planned to meet rapidly growing international demand.

Commenting on today’s announcement, Simon Cartmell, Chief Executive Officer of ApaTech said: “ApaTech is a British success story on the world stage. The science, developed at Queen Mary University London, is now in use by surgeons in 20 countries around the world. Most importantly Actifuse is providing improved outcomes for patients and their surgeons”.

“Everyone connected with ApaTech is delighted to be part of this success story and very proud to be recognised by the Sunday Times and the Financial Times for both the company’s excellent sales growth and technology achievements.”

Ends

Further Information:

ApaTech www.apatech.com
Simon Cartmell, CEO 020 8731 4640
Simon.cartmell@apatech.com


Waughton www.waughton.com
Robin Hepburn/Victoria Nicholson 020 7796 9999
rhepburn@waughton.com

Notes to Editors:

About ApaTech

ApaTech's technology is based on extensive research to design the optimum material and structure for safe, effective bone grafting.

ApaTech’s research has created Actifuse, a product with unique silicate substituted calcium phosphate chemistry, produced as a scaffold with consistent interconnected micro- and macroporosity. As a result of its unique properties Actifuse has been shown to accelerate the rate and quality of bone formation compared to other synthetic and biological solutions available today. Actifuse is available as a range of granule and microgranule formulations, including an EasyPrep applicator and as an Advanced Bone matriX, Actifuse ABX mouldable graft material.

ApaTech was spun out of Queen Mary University London in 2001, funded by 3i, who have participated in all funding rounds and are the Company’s largest shareholder. The pivotal Series B round in April 2004 was lead by UK venture capital firm, MTI Partners. To date the Company has raised £12.2m of equity principally from 3i plc and MTI plus £3.5m of debt from Noble Ventures

ApaTech is based in Elstree, UK, Foxborough, Mass, USA and Berlin, Germany. More details can be found at<


Publisher Contact Information:

ApaTech Ltd
+44 20 8731 4640
Simon.cartmell@apatech.com

Company profile of ApaTech Ltd
Past press releases of ApaTech Ltd.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.